133 results
424B5
BMY
Bristol-Myers Squibb Co.
16 Feb 24
Prospectus supplement for primary offering
4:34pm
annual or special meeting of the stockholders. During the time the holders of preferred stock are entitled to elect two additional directors … by the affirmative vote of the holders of record of a majority of our shares entitled to vote, at any annual or special meeting, or, by a vote
424B2
BMY
Bristol-Myers Squibb Co.
13 Feb 24
Prospectus for primary offering
8:00am
, will be entitled to elect two directors at the next annual or special meeting of the stockholders. During the time the holders of preferred stock … , at any annual or special meeting, or, by a vote of the majority of our board of directors, at any regular or special meeting at which a quorum
DFAN14A
KRTX
Karuna Therapeutics Inc
22 Dec 23
Additional proxy materials by non-management
4:36pm
of the special meeting relating to the proposed acquisition. This communication is not a substitute for the proxy statement or any other document … . The definitive proxy statement and proxy card will be delivered to the stockholders of Karuna Therapeutics in advance of the special meeting relating
DFAN14A
s0ue6xb 5h5x
22 Dec 23
Additional proxy materials by non-management
4:21pm
DFAN14A
EX-99.1
t33hhtpt5mw2zel0n20
22 Dec 23
Additional proxy materials by non-management
4:21pm
8-K
EX-99.1
01uo sk669l9e33c4oz
22 Dec 23
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
4:15pm
8-K
hg7j5277 ps
22 Dec 23
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
4:15pm
424B5
jazpcugz4
1 Nov 23
Prospectus supplement for primary offering
4:16pm
424B3
158iepzb
30 Oct 23
Prospectus supplement
8:05am
DFAN14A
6ur5zto jd2o74w0fl
10 Oct 23
Additional proxy materials by non-management
6:48am
DEFA14A
n97s5q643
10 Apr 23
Additional proxy soliciting materials
5:12pm
8-K
EX-99.3
fjxlqu4w
29 Apr 22
Bristol Myers Squibb Reports First Quarter Financial Results for 2022
7:42am
DEFA14A
01rzh2 0jqiyth3b
20 Apr 22
Additional proxy soliciting materials
4:30pm
424B5
ls9y2obnjes 62
17 Feb 22
Prospectus supplement for primary offering
4:47pm
424B3
7x10 rcmn
15 Feb 22
Prospectus supplement
9:13am
8-K
EX-99.3
0pnzopjypvskg2
4 Feb 22
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
7:50am